Down-regulation of tissue factor by siRNA increased doxorubicin-induced apoptosis in human neuroblastoma

Jun Fang1, Hao Tang, Linghui Xia

  • 1Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Molecular Targeting Laboratory of Hubei Province, Wuhan 430022, China. fangjunth@126.com

Insights

Inhibiting tissue factor (TF) in neuroblastoma cells enhances doxorubicin

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Neuroblastoma is a pediatric cancer with varying treatment responses.
  • Tissue Factor (TF) is implicated in cancer progression and may influence chemotherapy resistance.

Purpose of the Study:

  • To investigate the role of Tissue Factor (TF) in doxorubicin-induced apoptosis in human neuroblastoma cells.
  • To determine if TF knockdown enhances the efficacy of doxorubicin treatment.

Main Methods:

  • TF expression was analyzed using Western blotting.
  • TF was silenced in SK-N-MC neuroblastoma cells using TFsiRNA-pSUPER plasmid transfection.
  • Doxorubicin cytotoxicity was assessed via WST assay.
  • Apoptosis markers (Caspase-3, PARP cleavage) and apoptotic cell counts were evaluated.

Main Results:

  • Human neuroblastoma cells (SK-N-MC) express high levels of TF.
  • TF knockdown was successfully achieved in a dose-dependent manner.
  • Inhibition of TF significantly reduced cell viability and enhanced doxorubicin-induced apoptosis, evidenced by increased Caspase-3 and PARP cleavage.
  • TF knockdown increased the number of apoptotic cells when treated with doxorubicin.

Conclusions:

  • Down-regulation of TF expression using siRNA enhances doxorubicin-induced apoptosis in human neuroblastoma cells.
  • TF may contribute to chemotherapy resistance in neuroblastoma, potentially by modulating apoptosis.
  • Targeting TF could be a therapeutic strategy to overcome doxorubicin resistance in neuroblastoma.

Related Concept Videos